20 July 2017 EMA/CAT/462094/2017 Inspections, Human Medicines Pharmacovigilance and Committees Division

CAT monthly report of application procedures, guidelines and related documents on advanced therapies July 2017 meeting

The Committee for Advanced Therapies (CAT) held its 95th CAT meeting on 12 – 14 July 2017. The CAT Monthly Report includes statistical data on CAT scientific recommendations on Advanced Therapy Medicinal Product (ATMP) classification, certifications, initial evaluations, CAT contributions to Scientific Advice and Paediatric Investigation Plans, as well as variations, line extensions, renewals.

Scientific recommendation on advanced therapy product classification Further to consultation with the European Commission, the CAT finalised 4 scientific recommendations on the classification of advanced therapy medicinal products. The following products were classified as somatic cell therapy medicinal products: •

Autologous uncultured cells of stromal vascular fraction intended for the relief of symptoms of osteoarthritis.



Human umbilical cord blood-derived mesenchymal stem cells intended for the treatment of atopic dermatitis.

The following products were classified as tissue engineered products: •

Autologous keratinocytes intended for the treatment of burns and chronic, severe wounds.



Autologous chondrocytes intended for the repair of single symptomatic cartilage defects of the knee.

Organisational matters •

CAT adopted the concept paper on the revision of the guideline on quality, non-clinical and clinical aspects of medicinal products containing genetically modified cells. The document will be published shortly.



CAT finalised the programme of the Expert Meeting on adeno-associated viral (AAV) vectors that will take place on 6 September 2017. This meeting is not open to the public.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact

An agency of the European Union

© European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged.



CAT discussed the preparation of the Expert meeting on genome editing that will take place on 18 October 2017. This meeting is organised jointly by CAT and the CHMP Pharmacogenomics Working Party (PGWP). CAT and PGWP members will discuss with experts from academia and industry the state of art in genome editing technologies, the current product developments and the potential consequences on existing EMA guidance. This meeting is not open to the public.

New ATMP related documents published on the EMA Website •

Development of non-substantially manipulated cell-based ATMPs: flexibility introduced via the application of the risk-based approach



GLP requirement for ATMPs

Overview of product-related activities The Committee discussed ongoing evaluation procedures for ATMPs and other related procedures as summarised in the following tables: Initial Evaluation of Marketing Authorisation Applications (MAA) for ATMP 2009

2010

2011

2012

2013

2014

2015

2016

2017

Total

3

1

2

3

2

2

1

1

1

16

1

0

1ii

1ii

2

1

1

2

1

10*

1i

0

1ii

0

0

0

2iii

0

0

4

1

1i

0

0

2

0

0

0

0

4

Submitted MAAs Positive draft Opinion Negative draft opinions Withdrawals

2

Ongoing MAAs * Corresponding to 9 ATMPs I Same product (Cerepro) ii Same product (Glybera) iii CAT adopted two negative draft opinions for the same product (Heparesc)

Variations (Type II) for authorised ATMP

Positive

2009

2010

2011

2012

2013

2014

2015

2016

2017

Total

0

0

1

1

9

4

3

6

3

27

Opinion

Scientific recommendation on advanced therapy classification 2009

2010

2011

2012

2013

2014

2015

2016

2017

Total

Submitted

22

19

12

22

20

28

61

60

28

272

Adopted

12

27

12

16

23

29

31

87

34

271

CAT monthly report of application procedures, guidelines and related documents on advanced therapies EMA/462094/2017

Page 2/3

Certification of quality and non-clinical data for small and medium-sized enterprises developing ATMPs 2009

2010

2011

2012

2013

2014

2015

2016

2017

Total

Submitted

1

0

0

1

3

1

1

2

1

10

Adopted

0

1

0

1

1

2

1

1

3

10

Scientific advice procedure for ATMPs

Number of

2009

2010

2011

2012

2013

2014

2015

2016

2017

Total

17

19

21

19

23

33

39

46

27

244

procedures

Paediatric Investigation Plans (PIP) for ATMPs

Number of

2009

2010

2011

2012

2013

2014

2015

2016

2017

Total

3

4

4

8

5

4

3

5

1

37

procedures

Prime Eligibility for ATMPs

Discussed Granted

2016

2017

Total

22

13

35

8

4

12

Upcoming meetings following the July 2017 CAT meeting The 96th meeting of the CAT will be held on 6 – 8 September 2017. NOTE: 1. This Monthly Report, the Agenda of this meeting, the Minutes of the previous CAT meeting and other documents can be found on the internet at the following location: European Medicines Agency - Committee meeting reports - CAT: Committee meeting reports 2. Specific information related to ATMPs and the activities of the CAT (role, responsibilities and composition) can be found at: European Medicines Agency - CAT - Committee for Advanced Therapies (CAT)

Thorsten Olski Head of Scientific Committees Secretariat Tel.: (+44-20) 3660 7684 [email protected]

CAT monthly report of application procedures, guidelines and related documents on advanced therapies EMA/462094/2017

Page 3/3

Monthly report CAT July 2017 - European Medicines Agency - Europa ...

Jul 20, 2017 - CAT monthly report of application procedures, guidelines ... industry the state of art in genome editing technologies, the current product developments and ... Development of non-substantially manipulated cell-based ATMPs: ...

107KB Sizes 1 Downloads 50 Views

Recommend Documents

July 2017 - European Medicines Agency - Europa EU
Jul 5, 2017 - Send a question via our website www.ema.europa.eu/contact ... non-proprietary names (INN) and therapeutic areas for all new ... also available in the monthly reports of the Committee for Orphan Medicinal Products (COMP).

July 2016 - European Medicines Agency - Europa EU
Jul 11, 2016 - EMA/COMP/451206/2016 ... Cannabidiol for treatment of graft-versus-host disease, Richardson Associates Regulatory ..... Best Regulatory.

July 2016 - European Medicines Agency - Europa EU
Information is selected based on recommendations from consulted patients, consumers ... need one of the following: a modern web browser; a web-based news reader or a ..... person developing the medicine must submit an application to the.

July 2016 - European Medicines Agency - Europa EU
Jul 4, 2016 - Send a question via our website www.ema.europa.eu/contact ... non-proprietary names (INN) and therapeutic areas for all new ... also available in the monthly reports of the Committee for Orphan Medicinal Products (COMP).

July 2016 - European Medicines Agency - Europa EU
For a list of RSS readers please refer to our RSS guide and follow the instructions ..... PCWP and HCPWP joint meeting: Workshop on social media - Sep 2016.

July 2018 - European Medicines Agency - Europa EU
Jul 12, 2018 - An agency of the European Union ... This list only includes information for medicines whose applications have been validated at the time the.

monthly figures - March 2017 - European Medicines Agency - Europa ...
Apr 13, 2017 - Information Management Division ... This document provides current information related to the volume and evaluation of .... Plasma master file.

monthly figures - May 2017 - European Medicines Agency - Europa EU
Jun 21, 2017 - Information Management Division ... This document provides current information related to the volume and evaluation of .... Plasma master file.

Annual report - European Medicines Agency - Europa EU
Jun 16, 2016 - Send a question via our website www.ema.europa.eu/contact ... Internal awareness raising events for 20th anniversary . ..... Social media.

CAT work plan 2017 - European Medicines Agency - Europa EU
Apr 12, 2017 - Member. Marc Turner. Scottish National Blood Transfusion. Service .... CAT will collaborate with the BWP and the HMA innovation network on this ... 1.3.3. Addressing the Environmental Risk assessment of ATMPs containing.

17-18 July 2017 - European Medicines Agency - Europa EU
Jul 24, 2017 - Send a question via our website www.ema.europa.eu/contact ... consultation will be published on the European Medicines Agency's website at:.

2017-12 INN Report - European Medicines Agency - Europa EU
Nov 28, 2017 - Information Management Division. Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use. December 2017. This document lists information on applications for centralised marketing auth

Annual activity report 2017 - European Medicines Agency - Europa EU
Jun 7, 2018 - The type IA/IB and type II variation validation checklists have been published on the EMA corporate website, to help applicants prepare.

monthly figures - February 2017 - European Medicines Agency
Mar 16, 2017 - Applicants can request a re-examination. The first four rows present the outcome of the evaluation before a re-examination (or a.